Replies to post #227448 on Biotech Values

[DewDiligence]

Maybe a small part, but that's all. The AMRN connection you're referring to is that GILD added Vascepa to one of a dozen or so trial arms in a phase-2 NASH trial in progress.

[miljenko]

Tg is not primary end point in aramchol (ARMOR, GLMD) trial. Reduction of the liver fat is surrogate secondary.